AstraZeneca’s oral breast-cancer drug camizestrant missed its primary goal in the pivotal SERENA-4 trial — a setback that landed just one week after the drug won an accelerated FDA approval in a different patient group.
What the trial tested
SERENA-4 enrolled patients with ER-positive, HER2-negative advanced breast cancer who had not yet had systemic therapy for advanced disease. It paired camizestrant with palbociclib (a CDK4/6 inhibitor) and compared that against the standard anastrozole plus palbociclib. The primary endpoint was progression-free survival (PFS) — how long patients live without their cancer worsening.
The result
Camizestrant showed a numerical improvement in PFS, but the difference did not reach statistical significance — so the trial failed its primary endpoint in this broad first-line population.
Why the timing stings — and the nuance
Just days earlier (September 4, 2026), the FDA had granted camizestrant an accelerated approval based on SERENA-6, which succeeded in a narrower group with emerging ESR1 mutations. So the picture is mixed rather than bleak: the drug works in a targeted setting but couldn’t beat standard therapy across an unselected first-line population. For AstraZeneca, it trims the drug’s potential ceiling in a competitive market. Business/clinical news, not investment or medical advice.